Back to search
FDAFDA · Food and drugs·Recall number D-0181-2015

CHORIONIC GONADOTROPIN, 4000 Units, sterile powder for reconstitution, glass vial, RX, Creative Compounds, Wilsonville, OR 97070

Published November 12, 2014 · Recall initiated: October 6, 2014

Summary

FDA records drug Class II recall D-0181-2015, published November 12, 2014 and initiated October 6, 2014. Recalling firm: Oregon Compounding Centers, Inc. dba Creative Compounds; Status: Terminated; Reported quantity: 145 vials; Lot: Lot #: 20140728@55, discard date: 1/14/2015; Lot #: 20140915@14, discard date: 3/8/2015. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

What to do

Voluntary: Firm initiated · Press Release

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Oregon Compounding Centers, Inc. dba Creative Compounds
Distributor
Oregon, Washington
Lot
Lot #: 20140728@55, discard date: 1/14/2015; Lot #: 20140915@14, discard date: 3/8/2015.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was CHORIONIC GONADOTROPIN, 4000 Units, sterile powder for reconstitution, glass vial, RX, Creative Compounds, Wilsonville, OR 97070 recalled?

Yes. FDA published recall D-0181-2015 on November 12, 2014. Reported hazard: Lack of Sterility Assurance: All lots of sterile products compounded by the pharmacy that are not expired due to concerns associated with quality control procedures that present a potential risk to sterility assurance that were observed during a recent FDA inspection.

What should I do if I have this product?

Voluntary: Firm initiated · Press Release